论文部分内容阅读
对现代序贯化疗方案抗药的进展期非何杰金淋巴瘤(NHL)31例患者联合应用米托蒽醌(NO)和大剂量阿糖胞苷(AC)进行治疗.31例患者均>15岁,其中男25例,女6例,中数年龄为47岁.按Kiel分类法及国立癌症研究院NHL病理分类法分为高级别组(18例)及低级别组(13例).难治是指对序贯化疗方案如CHOP/IMVP-16,COP-BLAM/IMVP-16,Pro-MACE/MOPP,MACOP-B方案原发抗药,或进行某些常规治疗方案CHOP,Pro-MACE,或M-BACOD时疾病进展的病例;CHOP或相应第一线治疗CR复发后对第二线方案(IMVP 16, Pro-MACE,或M-BA-
Thirty-one patients with advanced non-Hodgkin’s lymphoma (NHL) resistant to modern sequential chemotherapy regimens were treated with mitoxantrone (NO) and high-dose cytarabine (AC). All 31 patients had > At the age of 15, there were 25 males and 6 females. The median age was 47 years. According to the Kiel classification method and National Cancer Institute NHL pathological classification, it was divided into high-grade group (18 cases) and low-grade group (13 cases). Refractory refers to the initial resistance to sequential chemotherapy regimens such as CHOP/IMVP-16, COP-BLAM/IMVP-16, Pro-MACE/MOPP, MACOP-B regimens, or some conventional treatment regimens CHOP, Pro- Cases of disease progression at the time of MACE, or M-BACOD; CHVP or corresponding first-line treatment CR recurrence after second-line regimen (IMVP 16, Pro-MACE, or M-BA-